Imatinib mesylate (STI571) treatment in patients with chronic-phase chronic myelogenous leukaemia previously submitted to autologous stem cell transplantation-Reference-Cited by-同舟云学术

Imatinib mesylate (STI571) treatment in patients with chronic-phase chronic myelogenous leukaemia previously submitted to autologous stem cell transplantation

Published:2003-02 Issue:3 Volume:120 Page:500-504
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:

Author:

Cervantes Francisco,Hernández-Boluda Juan-Carlos,Odriozola Jesús,Camós Mireia,Villalón Lucía,Martínez-Climent José-Angel,Del Campo Raquel,García-Conde Javier,Montserrat Emilio

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1046/j.1365-2141.2003.04077.x/fullpdf

Reference21 articles.

1. Safety and efficacy of STI-571 (GleevecTM) in patients with bcr/abl-positive chronic myelogenous leukemia (CML) after autologous peripheral blood stem cell transplantation;Beck;Blood,2001

2. Autologous transplantation therapy for chronic myelogenous leukemia;Bhatia;Blood,1997

3. Autografting with Philadelphia chromosome-negative mobilized hematopoietic progenitor cells in chronic myelogenous leukemia;Carella;Blood,1999

4. Induction of chronic myelogenous leukemia in mice by the P210 bcr/abl gene of the Philadelphia chromosome;Daley;Science,1990

5. STI571 (Gleevec/Glivec, imatinib) versus interferon (IFN) + cytarabine as initial therapy for patients with CML: results of a randomized study;Druker;Journal of Clinical Oncology,2002

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The prevalence of hepatic and thyroid toxicity associated with imatinib treatment of chronic myeloid leukaemia: a systematic review;International Journal of Clinical Pharmacy;2023-12-26

2. Autologous stem cells collected after debulking by high dose chemotherapy in late phase chronic myeloid leukemia may improve Imatinib efficacy;Transfusion and Apheresis Science;2007-02

3. Livedoid Skin Reaction Probably Due to Imatinib Therapy;Annals of Pharmacotherapy;2007-01

4. Update on practical aspects of the treatment of chronic myeloid leukemia with imatinib mesylate;Current Hematologic Malignancy Reports;2006-09

5. Plasma cell dyscrasias and leukemias;Cancer Chemotherapy and Biological Response Modifiers Annual;2005